SBIR/STTR Research Award

Simultaneous Control of Expression of Two Genes in Mammalian Tissue Culture

Award identifier d38356e6f8886188c710796617d55a8aeca5f54255b62f3084b39feeb34e98e7Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$132,223

Program and phase

SBIR · Phase I

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NEW ENGLAND BIOLABS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
EDKJNT8DADG8
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The ability to control expression of a cloned gene both temporally and quantitatively is critical to the study of its function. For two interacting genes or gene products, the ability to control both the timing and level of expression, independently, is essential. A research tool that performed this function would be novel, timely and of significant value to the research community. Toward this end, we have identified two ecdysone receptor (EcR) Ligand Binding Domain (LBD) mutants that bind two different small molecule agonist ligands, orthogonally. Each EcR(LBD) mutant has been fused to a different DNA Binding Domain (DBD) motif, GAL4 DBD and LexA DBD. Using these EcR fusions we have demonstrated their ability to control gene expression of two reporter genes in mammalian tissue culture, independently in a ligand- dependent manner. We propose here to further test the system in a variety of mammalian cell lines under different conditions. We also propose to engineer the components into a simple, two-plasmid format, with one plasmid containing all of the components that drive the system and the other plasmid acting as a cloning vector for two genes. Positive control reporter vectors and stable cell lines will also be developed to complement it. In Phase II we will develop the in vivo use of RheoPlex by determining the tissue distribution of the two ligands, activity of the receptors and construct transgenic mice. We will also use RheoPlex to explore the coordination of DNMT1 and G9a in methylating chromatin during DNA replication. 1 Precise temporal, spatial and quantitative control over the expression of transgenes via external application of small molecules is an extremely powerful tool for gene function analysis both in vitro and in vivo. In addition, it can greatly facilitate the production of therapeutic proteins and would be crucial for gene and cell therapy applications. With the recent availability of the genome sequences of a variety of mammals, scientific attention has transferred from gene identification to functional studies. The tool under development will provide cell and molecular biologists with a unique and valuable tool to study the function of more than one gene simultaneously within the same cell. This will greatly facilitate the in vitro and in vivo study of interacting genes, gene products, genetic pathways and biochemical pathways.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

40 SBIR/STTR records share this UEI (1994–2013). Reported award amounts total $12,787,343. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.